Answers are grounded in this paper and cite their sources.
Observational study reveals associations between CSF biomarkers and MRI markers in probable cerebral amyloid angiopathy, suggesting direct tracking of vascular amyloid burden.
Cerebral amyloid angiopathy (CAA) is currently diagnosed using MRI-based Boston criteria. However, imaging markers represent downstream consequences of vascular injury and may not fully reflect disease severity. CSF biomarkers, particularly β-amyloid 1–42 (Aβ42) and β-amyloid 1–40 (Aβ40), may provide a more direct measure of vascular amyloid burden. We investigated the association between CSF biomarkers and hemorrhagic and nonhemorrhagic MRI markers of disease severity in probable CAA.
No takes yet. Share an insight, caveat, or question.
Beaufort et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: